Invivyd reports Q3 EPS (6c) vs (51c) last year

Reports Q3 revenue $13.129M, consensus $13.1M. “With a strengthened balance sheet and a clear path forward for VYD2311 with recent IND clearance and U.S. Food and Drug Administration alignment, Invivyd (IVVD) is well-poised to provide Americans with antibody protection as an alternative to COVID vaccination,” said Marc Elia, Chairman of the Board of Directors at Invivyd. “Given the current unmet need, we are preparing for our pivotal studies and potential commercial launch of VYD2311 with urgency and to secure Invivyd’s place as the leader in providing antibodies to prevent people from becoming sick with COVID. We are also looking at pathogens beyond COVID because humankind may benefit from additional, high quality immune power in preventing these illnesses.”